NCT02723955: Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)

NCT02723955
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patient must have tumors that are MSI-H to be eligble
Exclusions: Patients with untreated symtomatic brain metastases- see trial for details; Patients with carcinomatous meningitis or leptomeningeal spread are excluded regardless of clinical stability; Patients have received more than 5 prior lines of therapy for advanced disease including both standards of care & investigational therapies
https://ClinicalTrials.gov/show/NCT02723955

Comments are closed.

Up ↑